MediGene to Present at the Piper Jaffray Conference in London Internet live webcast available at MARTINSRIED/MUNICH, Germany, June 20, 2008.The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) will give a presentation at the Piper Jaffray Conference in London.
The speech will be made...
Allergan buys QLT's acne drug Under the terms of the agreement, QLT will receive a one-time cash payment of approximately $150 million upon closing, which is expected to occur in the third quarter of 2008.The transaction has been approved by the board of directors of...
Research and Markets: QLT Inc: Premium Company Profile - Available Now DUBLIN, Ireland-- (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/reports/c94190) has announced the addition of 'QLT Inc: Premium Company Profile' to their offering.QLT was originally focused on discovering,...
QLT sells acne medication rights to Allergan Vancouver pharmaceutical company QLT Inc.has taken a major step in its planned downsizing with the sale of a key drug for $150-million (U.S.) in cash.
QLT said yesterday that it has sold worldwide rights to its acne medication Aczone to...
QLT to Sell Acne Vulgaris Treatment to Allergan for $150M GEN News Highlights GEN News Highlights QLTis transfering rights covering an acne vulgaris treatment to a subsidiary of Allergan for roughly $150 million.Aczone is a topical medicine approved in the U.S.
and Canada.
The divestment of...
Research and Markets: QLT Inc: Premium Company Profile Available Now Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c94192) has announced the addition of 'QLT Inc: Premium Company Profile' to their offering QLT was originally focused on discovering, developing and commercializing...
Research and Markets: QLT Inc: Premium Company Profile - Available Now - Research and Markets (http://www.researchandmarkets.com/reports/c94190) has announced the addition of 'QLT Inc: Premium Company Profile' to their offering.QLT was originally focused on discovering, developing and commercializing...
QLT announces positive Health Canada decision on Aczone(R) VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc.announced today that Health Canada has completed its review of QLT USA, Inc.'s labeling supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate dehydrogenase (G6PD)...
QLT announces positive Health Canada decision on Aczone(R) VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc.(NASDAQ: QLTI; TSX: QLT) announced today that Health Canada has completed its review of QLT USA, Inc.'s labeling supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate...
QLT announces positive Health Canada decision on Aczone(R) VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc.announced today that Health Canada has completed its review of QLT USA, Inc.'s labeling supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate dehydrogenase (G6PD)...
Arab investor in talks with MediGene: sources FRANKFURT (Reuters) - An Arabic investor is in talks with MediGene, with options including taking a stake in the German biotech company, sources familiar with the matter said on Monday.'There is a major interest,' one source told Reuters....
European Regulatory Authority (EMEA) Recommends Granting of Marketing Authorization for MediGene's Drug Oracea A new era for MediGene: first drug to be marketed by the company itself MARTINSRIED/MUNICH, Germany, 25.April 2008.
MediGene AG (Frankfurt, Prime Standard: MDG) announced that the European Medicines Agency (EMEA) Committee for Medicinal...
